This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Merrimack (MACK) reports wider-than-expected loss in the first quarter.
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
by Zacks Equity Research
Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
by Zacks Equity Research
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
Why Is Allergan (AGN) Stock Falling Today?
by Taye Baldinazzo
Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Shire Sells Oncology Unit Ahead of Takeda's Potential Offer
by Zacks Equity Research
Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.
Shire (SHPG) is in Overbought Territory: What's Next?
by Zacks Equity Research
Shire plc (SHPG) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Shire's Stock Continues to Rise as Takeda Sets Eyes On it
by Zacks Equity Research
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
Shire (SHPG) Soars: Stock Adds 12.2% in Session
by Zacks Equity Research
Shire (SHPG) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack (MACK) reports narrower-than-expected loss in the fourth quarter due to lower operating expenses.
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.
Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Shire (SHPG) will report its Q4 results on Feb 14, 2018.
Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales
by Zacks Equity Research
Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Shire Gets FDA Nod for Cinryze Tech Transfer to New Site
by Zacks Equity Research
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.
Nektar Boasts Strong Pipeline, Competition Remains a Woe
by Zacks Equity Research
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
by Zacks Equity Research
Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
by Zacks Equity Research
Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
by Zacks Equity Research
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Shire's New Formulation of Oncaspar Gets Approval in Europe
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
by Zacks Equity Research
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
by Zacks Equity Research
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Shire Gets Positive CHMP Opinion for Hemophilia A Drug
by Zacks Equity Research
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View
by Zacks Equity Research
Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.
Allergan (AGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.